{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:48:12Z","timestamp":1792082892682,"version":"4.4.0"},"reference-count":80,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,8,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Pivmecillinam is a prodrug of mecillinam, a semi-synthetic penicillin, that has recently been U.S. Food and Drug Administration approved for the treatment of uncomplicated urinary tract infections (UTIs) in the United States. Mecillinam demonstrates activity against a variety of common uropathogens, including Enterobacterales such as\n                      <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                      . Despite being available internationally for more than four decades, mecillinam retains high susceptibility rates against a variety of Enterobacterales, including some that produce extended-spectrum-\u03b2-lactamases (ESBL) and carbapenemases. Given extensive clinical experience and history with this agent outside the United States, this review highlights the available literature on pivmecillinam regarding susceptibility testing and implementation, empiric antibacterial activity with a focus on ESBL-producing isolates, optimal treatment dose, and duration, as well as adverse effects and tolerability. In the United States, the current lack of approved susceptibility tests will limit pivmecillinam use to empiric therapy. There is significant heterogeneity among clinical studies, limiting the ability to identify an optimal treatment regimen for most pathogens with certainty. Comparative data regarding pivmecillinam against other agents used for UTI treatment are similarly limited but do not suggest it is significantly different in terms of clinical outcomes when considering specific treatment regimens. Clinical data regarding pivmecillinam\u2019s use in UTI due to ESBL-producing Enterobacterales are less robust but appear supportive if used at higher doses and for longer durations. Pivmecillinam is generally well tolerated, with gastrointestinal-related complaints being the most common. In the future, the availability of susceptibility testing and clinical data for pivmecillinam against OXA-48-like-producing Enterobacterales could expand its therapeutic utility for UTI treatment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01824-24","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T14:11:38Z","timestamp":1753107098000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["New Perspectives on Antimicrobial Agents: Pivmecillinam"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7735-1130","authenticated-orcid":true,"given":"Brandon K.","family":"Hawkins","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0011qv509","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center College of Pharmacy","place":["Knoxville, USA"]},{"id":[{"id":"https:\/\/ror.org\/020f3ap87","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, University of Tennessee Medical Center","place":["Knoxville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9372-4210","authenticated-orcid":true,"given":"Helen","family":"Ding","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/020f3ap87","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, University of Tennessee Medical Center","place":["Knoxville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melphine M.","family":"Harriott","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03wmmfz90","id-type":"ROR","asserted-by":"publisher"}],"name":"Healthcare-Associated Infections and Antimicrobial Resistance Program of the Communicable and Environmental Diseases and Emergency Preparedness Division, Tennessee Department of Health","place":["Nashville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/020f3ap87","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, University of Tennessee Medical Center","place":["Knoxville, USA"]},{"name":"Department of Internal Medicine, Graduate School of Medicine, University of Tennessee Health Science Center","place":["Knoxville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07167-y"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220265"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac396"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae296"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000221856"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007998609110428"},{"key":"e_1_3_1_8_2","unstructured":"Pivya (pivmecillinam). Package insert. 2024. Florham Park NJ UTILITY therapeutics Ltd"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000237814"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.00737.x"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.9.5.793"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl198"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki451"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac226"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2024.08.013"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8020057"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(89)92086-2"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100842"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp017"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540152029909"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540410021072a"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2179"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2019.06.050"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3016.2012.01317.x"},{"key":"e_1_3_1_25_2","volume-title":"NCCLS supplement M100Performance standards for antimicrobial susceptibility testing","author":"NCCLS","year":"2002","unstructured":"NCCLS. 2002. NCCLS supplement M100. Performance standards for antimicrobial susceptibility testing. 12th ed. National Committee for Clinical Laboratory Standards.","edition":"12"},{"key":"e_1_3_1_26_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. 2025. Breakpoint tables for interpretation of MICs and zone diameters version 15.0. 2025. Available from: https:\/\/www.eucast.org\/clinical_breakpoints"},{"key":"e_1_3_1_27_2","volume-title":"CLSI supplement M100Performance standards for antimicrobial susceptibility testing","author":"CLSI","year":"2025","unstructured":"CLSI. 2025. CLSI supplement M100. Performance standards for antimicrobial susceptibility testing. Clinical Laboratory Standards Institute."},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.08.014"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-015-2498-3"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04819-14"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.08.021"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab401"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.627267"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae271"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac059"},{"key":"e_1_3_1_36_2","unstructured":"U.S. Food and Drug Administration. Devices@FDA. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/devicesatfda\/index.cfm. Retrieved 27 Mar 2025."},{"key":"e_1_3_1_37_2","first-page":"863","article-title":"In vitro activity of mecillinam and amoxicillin\/clavulanic acid against strains of Escherichia coli producing TEM-1, Oxa-1 and chromosomal beta-lactamases","volume":"38","author":"Marre R","year":"1988","unstructured":"Marre R, Schulz E. 1988. In vitro activity of mecillinam and amoxicillin\/clavulanic acid against strains of Escherichia coli producing TEM-1, Oxa-1 and chromosomal beta-lactamases. Arzneimittelforschung 38:863\u2013865.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.suppl_1.9"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11030356"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02402-18"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg028"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt368"},{"key":"e_1_3_1_43_2","unstructured":"Aurobindo Pharma - Milpharm Ltd. 2024. Pivmecillinam 200 mg film-coated tablets. Summary of product characteristics. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/4982\/smpc. Retrieved 20 Feb 2024."},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1680052"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad402"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.11.008"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001014"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00692-23"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.suppl_1.35"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1177\/20499361241228342"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.09.013"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00612-19"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.11.001"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01283-20"},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks215"},{"key":"e_1_3_1_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx087"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11101280"},{"key":"e_1_3_1_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.09.011"},{"key":"e_1_3_1_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/mbo3.941"},{"key":"e_1_3_1_60_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241288554"},{"key":"e_1_3_1_61_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11060751"},{"key":"e_1_3_1_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2017.03.012"},{"key":"e_1_3_1_63_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006058000800201"},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007998209110100"},{"key":"e_1_3_1_65_2","first-page":"1156","article-title":"Pivmecillinam treatment in acute cystitis. three versus seven days study","volume":"40","author":"Pitk\u00e4j\u00e4rvi T","year":"1990","unstructured":"Pitk\u00e4j\u00e4rvi T, Pyyk\u00f6nen ML, Kannisto K, Piippo T, Viita P. 1990. Pivmecillinam treatment in acute cystitis. three versus seven days study. Arzneimittelforschung 40:1156\u20131158.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_1_66_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007998409109580"},{"key":"e_1_3_1_67_2","doi-asserted-by":"publisher","DOI":"10.1080\/02813430601183074"},{"key":"e_1_3_1_68_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540110080728"},{"key":"e_1_3_1_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/3.suppl_b.121"},{"key":"e_1_3_1_70_2","first-page":"618","article-title":"Treatment of acute urinary tract infection with pivmecillinam: a randomised comparison of two dose levels","volume":"35","author":"Pettersson T","year":"1984","unstructured":"Pettersson T, Koskenniemi L, Tokola O. 1984. Treatment of acute urinary tract infection with pivmecillinam: a randomised comparison of two dose levels. Current Ther Res 35:618\u2013622.","journal-title":"Current Ther Res"},{"key":"e_1_3_1_71_2","first-page":"25","article-title":"A general practice evaluation of pivmecillinam given twice daily as a treatment for acute urinary tract infection","volume":"4","author":"Skinner JL","year":"1984","unstructured":"Skinner JL, Venables TL, Sheldon MG. 1984. A general practice evaluation of pivmecillinam given twice daily as a treatment for acute urinary tract infection. Pharmatherapeutica 4:25\u201331.","journal-title":"Pharmatherapeutica"},{"key":"e_1_3_1_72_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548709032384"},{"key":"e_1_3_1_73_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad010"},{"key":"e_1_3_1_74_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2011.0161"},{"key":"e_1_3_1_75_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt404"},{"key":"e_1_3_1_76_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085889"},{"key":"e_1_3_1_77_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky230"},{"key":"e_1_3_1_78_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S209255"},{"key":"e_1_3_1_79_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S163280"},{"key":"e_1_3_1_80_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa411"},{"key":"e_1_3_1_81_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07463-7"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01824-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01824-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:39:05Z","timestamp":1773178745000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01824-24"}},"subtitle":[],"editor":[{"given":"Ryan K.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":80,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,6]]}},"alternative-id":["10.1128\/aac.01824-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.01824-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"2025-07-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01824-24"}}